0001144204-18-009053.txt : 20180214 0001144204-18-009053.hdr.sgml : 20180214 20180214172240 ACCESSION NUMBER: 0001144204-18-009053 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 34 CONFORMED PERIOD OF REPORT: 20171231 FILED AS OF DATE: 20180214 DATE AS OF CHANGE: 20180214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALLIED HEALTHCARE PRODUCTS INC CENTRAL INDEX KEY: 0000874710 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 231370721 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19266 FILM NUMBER: 18613801 BUSINESS ADDRESS: STREET 1: 1720 SUBLETTE AVE CITY: ST LOUIS STATE: MO ZIP: 63110 BUSINESS PHONE: 3147712400 MAIL ADDRESS: STREET 1: 1720 SUBLETTE AVENUE CITY: ST LOUIS STATE: MO ZIP: 63110 10-Q 1 tv485561_10q.htm FORM 10-Q

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

xQuarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

For the quarterly period ended December 31, 2017

 

¨Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

For the transition period from ________ to ________

 

Commission File Number: 0-19266

 

ALLIED HEALTHCARE PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   25-1370721
(State or other jurisdiction of   (I.R.S. Employer
Incorporation or organization)   Identification No.)

 

1720 Sublette Avenue, St. Louis, Missouri 63110

(Address of principal executive offices, including zip code)

 

(314) 771-2400

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months (or for such shorter periods that the registrant was required to file such reports, and (2) has been subject to such filing requirements for the past ninety days. Yes   x   No   ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes   x   No   ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨   Accelerated filer ¨
Non-accelerated filer ¨ (Do not check if smaller reporting company) Smaller reporting company x
Emerging growth company ¨      

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes   ¨   No   x

 

The number of shares of common stock outstanding at January 31, 2018 is 4,013,537 shares.

 

 

 

 

 

 

INDEX

 

      Page
      Number
Part I – Financial Information  
     
  Item 1. Financial Statements  
       
    Statement of Operations -  Three and six months ended December 31, 2017 and 2016 (Unaudited) 3
       
    Balance Sheet - December 31, 2017 (Unaudited) and June 30, 2017 4 - 5
       
    Statement of Cash Flows - Six months ended December 31, 2017 and 2016 (Unaudited) 6
       
    Notes to Financial Statements (Unaudited) 7 – 12
       
  Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 13 – 17
       
  Item 3. Quantitative and Qualitative Disclosure about Market Risk 17
       
  Item 4. Controls and Procedures 17
       
Part II - Other Information  
       
  Item 1. Legal Proceedings 18
       
  Item 6. Exhibits 19
       
    Signature 19

 

“SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

 

Statements contained in this Report, which are not historical facts or information, are “forward-looking statements.” Words such as “believe,” “expect,” “intend,” “will,” “should,” and other expressions that indicate future events and trends identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, which could cause the outcome and future results of operations, and financial condition to be materially different than stated or anticipated based on the forward-looking statements. Such risks and uncertainties include both general economic risks and uncertainties, risks and uncertainties affecting the demand for and economic factors affecting the delivery of health care services, both in the United States and in our overseas markets, impacts of the U.S. Affordable Care Act, the outcome of litigation proceedings and specific matters which relate directly to the Company’s operations and properties as discussed in the Company’s annual report on Form 10-K for the year ended June 30, 2017. The Company cautions that any forward-looking statements contained in this report reflect only the belief of the Company or its management at the time the statement was made. Although the Company believes such forward-looking statements are based upon reasonable assumptions, such assumptions may ultimately prove inaccurate or incomplete. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement was made.

 

2

 

 

PART I. FINANCIAL INFORMATION

 

Item 1.Financial Statements

 

ALLIED HEALTHCARE PRODUCTS, INC.

STATEMENT OF OPERATIONS

(UNAUDITED)

 

   Three months ended   Six months ended 
   December 31,   December 31, 
   2017   2016   2017   2016 
                 
Net sales  $8,718,602   $8,268,978   $16,615,455   $16,709,391 
Cost of sales   6,809,684    6,573,722    13,349,469    13,456,965 
Gross profit   1,908,918    1,695,256    3,265,986    3,252,426 
                     
Selling, general and                    
administrative expenses   2,153,050    2,068,657    4,277,518    4,442,776 
Loss from operations   (244,132)   (373,401)   (1,011,532)   (1,190,350)
                     
Other (income) expenses:                    
     Interest income   (10)   (334)   (225)   (986)
     Other, net   185    1,633    236    1,671 
    175    1,299    11    685 
                     
Loss before income taxes   (244,307)   (374,700)   (1,011,543)   (1,191,035)
Provision for income taxes   136,386    -    136,386    - 
Net loss  $(380,693)  $(374,700)  $(1,147,929)  $(1,191,035)
                     
Basic loss per share  $(0.09)  $(0.09)  $(0.29)  $(0.30)
                     
Diluted loss per share  $(0.09)  $(0.09)  $(0.29)  $(0.30)
                     
Weighted average shares                    
outstanding - basic   4,013,537    4,013,537    4,013,537    4,013,537 
                     
Weighted average shares                    
outstanding - diluted   4,013,537    4,013,537    4,013,537    4,013,537 

 

See accompanying Notes to Financial Statements.

 

3

 

 

ALLIED HEALTHCARE PRODUCTS, INC.

BALANCE SHEET

ASSETS

 

   (Unaudited)     
   December 31,   June 30, 
   2017   2017 
         
Current assets:          
Cash and cash equivalents  $800   $995,704 
Accounts receivable, net of allowances of $170,000   3,573,712    3,362,438 
Inventories, net   9,106,188    8,511,954 
Income tax receivable   19,688    12,555 
Other current assets   243,492    315,678 
           
Total current assets   12,943,880    13,198,329 
           
Property, plant and equipment, net   5,278,595    5,734,041 
Deferred income taxes   547,377    683,763 
Other assets, net   -    20,516 
           
Total assets  $18,769,852   $19,636,649 

 

See accompanying Notes to Financial Statements.

 

(CONTINUED)

 

4

 

 

ALLIED HEALTHCARE PRODUCTS, INC.

BALANCE SHEET

(CONTINUED)

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

   (Unaudited)     
   December 31,   June 30, 
   2017   2017 
         
Current liabilities:          
Accounts payable  $2,079,731   $1,440,403 
Other accrued liabilities   1,650,417    2,009,966 
Total current liabilities   3,730,148    3,450,369 
           
Commitments and contingencies          
           
Stockholders’ equity:          
Preferred stock; $0.01 par value; 1,500,000 shares authorized; no shares issued and outstanding   -    - 
Series A preferred stock; $0.01 par value; 200,000 shares authorized; no shares issued and outstanding   -    - 
Common stock; $0.01 par value; 30,000,000 shares authorized; 5,213,902 shares issued at December 31, 2017 and June 30, 2017; 4,013,537 shares outstanding at December 31, 2017 and June 30, 2017   52,139    52,139 
Additional paid-in capital   48,486,743    48,485,390 
Accumulated deficit   (12,518,390)   (11,370,461)
Less treasury stock, at cost; 1,200,365 shares at December 31, 2017 and June 30, 2017, respectively   (20,980,788)   (20,980,788)
Total stockholders’ equity   15,039,704    16,186,280 
Total liabilities and stockholders’ equity  $18,769,852   $19,636,649 

 

See accompanying Notes to Financial Statements.

 

5

 

 

ALLIED HEALTHCARE PRODUCTS, INC.

STATEMENT OF CASH FLOWS

(UNAUDITED)

 

   Six months ended 
   December 31, 
   2017   2016 
         
Cash flows from operating activities:          
Net loss  $(1,147,929)  $(1,191,035)
Adjustments to reconcile net loss to net cash used in operating activities:          
           
Depreciation and amortization   475,962    562,963 
Stock based compensation   1,353    1,202 
Provision for doubtful accounts and sales          
returns and allowances   1,076    10,641 
Deferred taxes   136,386    - 
           
Changes in operating assets and liabilities:          
Accounts receivable   (212,350)   816,950 
Inventories   (594,234)   24,321 
Income tax receivable   (7,133)   (6,297)
Other current assets   72,186    39,633 
Accounts payable   639,328    (500,377)
Other accrued liabilities   (359,549)   (602,974)
Net cash used in operating activities   (994,904)   (844,973)
           
           
Cash flows from investing activities:          
Capital expenditures   -    (11,497)
Net cash used in investing activities   -    (11,497)
           
Net decrease in cash and cash equivalents   (994,904)   (856,470)
Cash and cash equivalents at beginning of period   995,704    1,703,663 
Cash and cash equivalents at end of period  $800   $847,193 

 

See accompanying Notes to Financial Statements.

 

6

 

 

ALLIED HEALTHCARE PRODUCTS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

1. Summary of Significant Accounting and Reporting Policies

 

Basis of Presentation

 

The accompanying unaudited financial statements of Allied Healthcare Products, Inc. (the “Company”) have been prepared in accordance with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should be read in conjunction with the financial statements and notes to the financial statements thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2017.

 

Recently Issued Accounting Guidance

 

In May 2014, the FASB and International Accounting Standards Board jointly issued new principles-based accounting guidance for revenue recognition that will supersede virtually all existing revenue guidance. The core principle of this guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. To achieve the core principle, the guidance establishes the following five steps: 1) identify the contract(s) with a customer, 2) identify the performance obligation in the contract, 3) determine the transaction price, 4) allocate the transaction price to the performance obligations in the contract, and 5) recognize revenue when (or as) the entity satisfies a performance obligation. The guidance also details the accounting treatment for costs to obtain or fulfill a contract. Lastly, disclosure requirements have been enhanced to provide sufficient information to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. This guidance was effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. In July 2015, the FASB affirmed its proposal to defer the effective date by one year. In May 2016, the FASB issued improvements and practical expedients to the standard that included clarification of the collectability criterion, noncash considerations as well as clarification of options at transition. In December 2016, the FASB issued additional corrections and improvements. The Company is in the process of evaluating the impact of this guidance. This new guidance, will likely result in a change in the nature and extent of the related footnote disclosures. The Company plans to adopt the new guidance when effective and presently anticipates adopting on a modified retrospective basis to each prior reporting period presented with the election of applicable practical expedients.

 

7

 

 

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”), which requires lessees to recognize assets and liabilities for leases with lease terms of more than 12 months and disclose key information about leasing arrangements. Consistent with current U.S. GAAP, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. The update is effective for reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is in the process of evaluating the impact of this update on its financial statements.

 

Fair Value of Financial Instruments

 

The Company’s financial instruments consist of cash and cash equivalents, accounts receivable and accounts payable. The carrying amounts for cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments.

 

2. Inventories

 

Inventories are comprised as follows:

 

   December 31, 2017   June 30, 2017 
         
Work-in progress  $472,699   $468,839 
Component parts   7,902,227    7,271,908 
Finished goods   2,320,593    2,368,855 
Reserve for obsolete and excess inventories   (1,589,331)   (1,597,648)
   $9,106,188   $8,511,954 

 

3. Earnings per share

 

Basic earnings per share are based on the weighted average number of shares of all common stock outstanding during the period. Diluted earnings per share are based on the sum of the weighted average number of shares of common stock and common stock equivalents outstanding during the period. The number of basic and diluted shares outstanding for the three and six months ended December 31, 2017 and 2016 were 4,013,537.

 

4. Commitments and Contingencies

 

Legal Claims

 

The Company is subject to various investigations, claims and legal proceedings covering a wide range of matters that arise in the ordinary course of its business activities. The Company intends to continue to conduct business in such a manner as to avert any FDA action seeking to interrupt or suspend manufacturing or require any recall or modification of products.

 

8

 

 

The Company has recognized the costs and associated liabilities only for those investigations, claims and legal proceedings for which, in its view, it is probable that liabilities have been incurred and the related amounts are estimable. Based upon information currently available, management believes that existing accrued liabilities are sufficient.

 

Stuyvesant Falls Power Litigation. The Company is currently involved in litigation with Niagara Mohawk Power Corporation d/b/a National Grid (“Niagara”), which provides electrical power to the Company’s facility in Stuyvesant Falls, New York, and one other party. The Company maintains in its defense of the lawsuit that it is entitled to a certain amount of free electricity based on covenants running with the land which have been honored for more than a century. After the commencement of the litigation, Niagara began sending invoices to the Company for electricity used at the Company’s Stuyvesant Falls plant. Niagara’s attempts to collect such invoices were stopped in December 2010 by a temporary restraining order. Among other things, Niagara seeks as damages the value of electricity received by the Company without charge. The total value of electricity at issue in the litigation is not known with certainty and Niagara has alleged different amounts of damages. Niagara alleged in its Second Amended Verified Complaint, dated February 6, 2012, damages of approximately $469,000 in free electricity from May 2003 through May 2010. Niagara also alleged in its Motion For Summary Judgment, filed on March 14, 2014, damages of approximately $492,000 in free electricity from May 2010 through the date of the filing. In April 2015, Allied received an invoice for electrical power at the Stuyvesant Falls plant with an “Amount Due” balance of $696,000 as of March 31, 2015 without any description as to the period of time covered by the invoice.

  

The Company filed a Motion for Summary Judgment on March 14, 2014, seeking dismissal of Niagara’s claims and oral arguments on the motions were held on June 13, 2014. On October 1, 2014, the Court granted the Company’s motion, denied Niagara’s motion and ruled that the Company is entitled to receive electrical power pursuant to the power covenants. On October 26 and October 30, 2014, Niagara and the other party filed separate notices of appeal of the Court’s decision. On March 31, 2016 the Supreme Court of New York, Appellate Division, Third Department reversed the trial court decision and held that the free power covenants are no longer enforceable. The Company’s application for leave to appeal this ruling was dismissed as premature by the New York Court of Appeals on September 20, 2016. On May 26, 2017 the Company again moved for leave to appeal the March 31, 2016 decision. That motion was granted on October 7, 2017 by the New York State Court of Appeals.

 

9

 

 

The appellate decision terminated the enforceability of the free power covenants as of March 31, 2016. The appellate decision did not order the Company to pay any amounts for power consumed prior to such date and the Company believes that it is not liable for any such damages as a result of the appellate decision. On December 21, 2016, Niagara filed a motion to the trial court asking that it hold additional proceedings to establish what damages, if any, are owed to Niagara as the result of the appellate decision. The Company filed its response on January 23, 2017. On April 25, 2017, the court denied Niagara’s motion in its entirety finding that no damages could be awarded based on the Appellate Division’s decision. Niagara has filed a Notice of Appeal from that decision, but to date, has not filed the appeal.

 

As of December 31, 2017, the Company has not recorded a provision for this matter. The Company commenced paying for power at the Stuyvesant Falls facility in April 2016.

 

Employment Contract

 

The Company has entered into an employment contract with its chief executive officer with annual renewals. The contract includes termination without cause and change of control provisions, under which the chief executive officer is entitled to receive specified severance payments generally equal to two times ending annual salary if the Company terminates his employment without cause or he voluntarily terminates his employment with “good reason.” “Good Reason” generally includes changes in the scope of his duties or location of employment but also includes (i) the Company’s written election not to renew the Employment Agreement and (ii) certain voluntary resignations by the chief executive officer following a “Change of Control” as defined in the Agreement.

 

5. Financing

 

On February 27, 2017, Allied Healthcare Products, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Credit Agreement”) with Summit Financial Resources, L.P. (“Summit”) pursuant to which the Company obtained a secured revolving credit facility (the “Credit Facility”). The Company’s obligations under the Credit Facility are secured by all of the Company’s personal property, both tangible and intangible, pursuant to the terms and subject to the conditions set forth in the Credit Agreement. Availability of funds under the Credit Agreement is based on the Company’s accounts receivable and inventory but will not exceed $2,000,000. At December 31, 2017 availability under the agreement was $2,000,000.

 

The Credit Facility will be available, subject to its terms, on a revolving basis until it expires on February 27, 2019, at which time all amounts outstanding under the Credit Facility will be due and payable. Advances will bear interest at a rate equal to 2.00% in excess of the prime rate as reported in the Wall Street Journal. Interest is computed based on the actual number of days elapsed over a year of 360 days. In addition to interest, the Credit facility requires that the Company pay the lender a monthly administration fee in an amount equal to forty-seven hundredths percent (0.47%) of the average outstanding daily principal amount of loan advances for the each calendar month, or portion thereof.

 

10

 

 

Regardless of the amount borrowed under the Credit Facility, the Company will pay a minimum amount of .25% (25 basis points) per month on the maximum availability ($5,000 per month). In the event the Company prepays or terminates the Credit Facility, the Company will be obligated to pay an amount equal to twelve months of minimum monthly payments, minus the number of months elapsed since the effective date of the Credit Agreement.

 

Under the Credit Agreement, advances are generally subject to customary borrowing conditions and to Summit’s sole discretion to fund the advances. The Credit Agreement also contains covenants with which the Company must comply during the term of the Credit Facility. Among other things, such covenants require the Company to maintain insurance on the collateral, operate in the ordinary course and not engage in a change of control, dissolve or wind up the Company.

 

The Credit Agreement also contains certain events of default including, without limitation: the failure to make payments when due; the material breach of representations or warranties contained in the Credit Agreement or other loan documents; cross-default with other indebtedness of the Company; the entry of judgments or fines that may have a material adverse effect on the Company; failure to comply with the observance or performance of covenants contained in the Credit Agreement or other loan documents; insolvency of the Company, appointment of a receiver, commencement of bankruptcy or other insolvency proceedings; dissolution of the Company; the attachment of any state or federal tax lien; attachment or levy upon or seizure of the Company’s property; or any change in the Company’s condition that may have a material adverse effect. After an event of default, and upon the continuation thereof, the principal amount of all loans made under the Credit Facility would bear interest at a rate per annum equal to 20.00% above the otherwise applicable interest rate (provided, that the interest rate may not exceed the highest rate permissible under law), and Summit would have the option to accelerate maturity and payment of the Company’s obligations under the Credit Facility.

 

At December 31, 2017, the Company had no aggregate indebtedness, including capital lease obligations, short-term debt and long term debt. The prime rate as reported in the Wall Street Journal was 4.50% on December 31, 2017.

 

The Company was in compliance with all of the covenants associated with the Credit Facility at December 31, 2017.

 

6. Income Taxes

 

The Company accounts for income taxes under ASC Topic 740: “Income Taxes.” Under ASC 740, the deferred tax provision is determined using the liability method, whereby deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and income tax bases of assets and liabilities using presently enacted tax rates. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. 

 

11

 

 

In the three and six months ended December 31, 2017 the Company recorded the tax benefit of losses incurred in the amount of approximately $75,000 and $367,000, respectively.  As the realization of the tax benefit of the net operating loss is not assured an additional valuation allowance of a like amount was recorded.

 

For the three and six months ended December 31, 2016 the Company recorded the tax benefit of losses incurred in the amount of approximately $130,000 and $436,000. As the realization of the tax benefit of the net operating loss is not assured an additional valuation allowance of approximately $130,000 and $436,000 was recorded.

 

U.S. Tax Reform

 

On December 22, 2017, President Trump signed into law new tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “TCJA”), which became effective January 1, 2018. The TCJA significantly revises U.S. tax law by, among other provisions lowering the U.S. federal statutory income tax rate from 35% to 21%, and eliminating or reducing certain income tax deductions.

 

ASC Topic 740, requires the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. However, due to the complexity and significance of the TCJA’s provisions, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”) on December 22, 2017, which allows companies to record the tax effects of the TCJA on a provisional basis based on a reasonable estimate, and then, if necessary, subsequently adjust such amounts during a limited measurement period as more information becomes available. The measurement period ends when a company has obtained, prepared, and analyzed the information necessary to finalize its accounting, but cannot extend beyond one year from enactment.

 

During the second quarter of fiscal 2018, the Company recorded a one-time charge of $136,386 within its income tax provision in connection with the TCJA, all of which related to the revaluation of the Company’s deferred tax assets and liabilities net of a resultant impact of the revaluation on the recorded valuation allowance. This one-time charge, which was recorded on a provisional basis, impacted the Company’s effective tax rate by increasing it from 0% and 0% to 56% and 13% for the three-month and six-month periods ended December 31, 2017, respectively, and lowered its basic and diluted earnings per share by $0.03 during each of these periods. The provisional amounts were based on the Company’s present interpretations of the TCJA and current available information, including assumptions and expectations about future events, such as its projected financial performance, and are subject to further refinement as additional information becomes available (including the Company’s actual full fiscal 2018 results of operations and financial condition, as well as potential new or interpretative guidance issued by the FASB or the Internal Revenue Service and other tax agencies) and further analyses are completed.

 

12

 

 

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Results of Operations

 

Three months ended December 31, 2017 compared to three months ended December 31, 2016

 

Allied had net sales of $8.7 million for the three months ended December 31, 2017, up $0.4 million from net sales of $8.3 million in the prior year same quarter resulting from higher orders and customer releases for shipment during the quarter. Domestic sales were up 3.0% while international sales, which represented 26.3% of second quarter sales, were up 13.0% from the prior year same quarter.

 

Orders for the Company’s products for the three months ended December 31, 2017 of $7.9 million were $0.2 million or 2.6% higher than orders for the prior year same quarter of $7.7 million., Domestic orders are up 6.1% over the prior year same quarter while international orders, which represented 19.0% of second quarter orders, were 8.9% lower than orders for the prior year same quarter. International sales and orders are subject to fluctuation in international demand. International sales can be impacted by political and economic uncertainty in regions and countries where the Company markets its products.

 

Gross profit for the three months ended December 31, 2017 was $1.9 million, or 21.8% of net sales, compared to $1.7 million, or 20.5% of net sales, for the three months ended December 31, 2016. The $0.2 million increase in gross profit is attributable to the increase in sales.

 

Selling, general and administrative expenses for the three months ended December 31, 2017 were $2.2 million compared to selling, general and administrative expenses of $2.1 million for the three months ended December 31, 2016. Legal expenses are approximately $82,000 higher than in the prior year.

 

Loss from operations was $244,132 for the three months ended December 31, 2017 compared to loss from operations of $373,401 for the three months ended December 31, 2016.

 

Allied had a loss before provision for income taxes in the second quarter of fiscal 2018 of $244,307 compared to loss before benefit from income taxes in the second quarter of fiscal 2017 of $374,700.  The Company’s tax provision net of valuation allowance reflects a tax provision of $136,386 and $0 for the three months ended December 31, 2017 and 2016.  In the both the quarters ended December 31, 2017 and 2016, the tax benefit of losses in the amount of approximately $75,000 and $130,000, respectively were fully offset by a valuation allowance of an equivalent amount.   In the quarter ended December 31, 2017, the Company revaluated its deferred tax assets, liabilities and valuation allowance to reflect the changes in tax rate occurring in connection with the TCJA. The impact of the revaluation was a current period provision for income taxes in the amount of $136,386. To the extent that the Company’s losses continue in future quarters, the tax benefit of those losses will be fully offset by a valuation allowance.

 

13

 

 

Net loss for the second quarter of fiscal 2018 was $380,693 or $0.09 per basic and diluted share compared to net loss of $374,700 or $0.09 per basic and diluted share for the second quarter of fiscal 2017. The weighted average number of common shares outstanding, used in the calculation of basic and diluted earnings per share for the second quarters of fiscal 2018 and 2017 were 4,013,537.

 

Six months ended December 31, 2017 compared to six months ended December 31, 2016

 

Allied had net sales of $16.6 million for the six months ended December 31, 2017, down $0.1 million, or 0.6% from net sales of $16.7 million in the prior year same period resulting from lower order levels and a decrease in customer orders released for shipment. Domestic sales were down 2.0% from the prior year same period while international sales were up 3.9% from the prior year same period. International business represented 25.5% of sales for the first six months of fiscal 2018. 

 

Orders for the Company’s products for the six months ended December 31, 2017 of $15.7 million were $0.2 million or 1.3% lower than orders for the prior year same period of $15.9 million. Domestic orders are down 2.1%, or $0.3 million over the prior year same period while international orders, which represented 22.8% of orders for the first six months of fiscal 2018, were 1.8% higher than orders for the prior year same period. The decrease in domestic orders reflects variability across the markets served. The increase in International orders was due to increased demand for the AHP300 Ventilator. International sales and orders are subject to fluctuation in international demand. These fluctuations are at times due to political and economic uncertainty internationally. International sales can be impacted by political and economic uncertainty in regions and countries where the Company markets its products.

 

Gross profit for the six months ended December 31, 2017 was $3.3 million, or 19.9% of net sales, compared to $3.3 million, or 19.8% of net sales, for the six months ended December 31, 2016.

 

Selling, general and administrative expenses for the six months ended December 31, 2017 were $4.3 million compared to selling, general and administrative expenses of $4.4 million for the six months ended December 31, 2016. Salaries and benefits were approximately $130,000 lower than in the prior year.

 

14

 

 

Loss from operations was $1.0 million for the six months ended December 31, 2017 compared to loss from operations of $1.2 million for the six months ended December 31, 2016.

 

Allied had a loss before provision for income taxes in the first six months of fiscal 2018 of $1,011,543 compared to loss before benefit from income taxes in the second quarter of fiscal 2017 of $1,191,035.  The Company’s tax provision net of valuation allowance reflects a tax provision of $136,386 and $0 for the six months ended December 31, 2017 and 2016.  In the both the two quarters ended December 31, 2017 and 2016, the tax benefit of losses in the amount of approximately $367,000 and $436,000, respectively were fully offset by a valuation allowance of an equivalent amount.   In the six months ended December 31, 2017, the Company revaluated its deferred tax assets, liabilities and valuation allowance to reflect the changes in tax rate occurring in connection with the TCJA. The impact of the revaluation was a current period provision for income taxes in the amount of $136,386. To the extent that the Company’s losses continue in future quarters, the tax benefit of those losses will be fully offset by a valuation allowance.

 

Net loss for the six months ended December 31, 2017 was $1,147,929 or $0.29 per basic and diluted share compared to net loss of $1,191,035 or $0.30 per basic and diluted share for the first six months of fiscal 2017. The weighted average number of common shares outstanding, used in the calculation of basic and diluted earnings per share for the first six months of fiscal 2018 and 2017 was 4,013,537.

 

Liquidity and Capital Resources

 

The Company believes that available resources, including available borrowing under the Credit Facility discussed below, are sufficient to meet operating requirements in the next twelve months from the date of this filing.

 

The Company’s working capital was $9.2 million at December, 2017 compared to $9.7 million at June 30, 2017. Cash and cash equivalents decreased by $1.0 million and Accounts Payable increased by $0.6 million. During fiscal 2018, these decreases in working capital were partially offset by a $0.6 million increase in Inventory, $0.2 million increase in Accounts Receivable and a $0.4 million decrease in Other Accrued Liabilities. Accounts Payable and Other Accrued Liabilities are subject to normal fluctuations in purchasing levels and the timing of payments within the quarter. Accounts Receivable was $3.6 million at December 31, 2017, an increase from $3.4 million at June 30, 2017. Accounts Receivable as measured in days sales outstanding (“DSO”) was 40 DSO at December 31, 2017; an increase from 39 DSO at June 30, 2017. The decrease in the Company’s cash in the quarter was primarily due to an increase in inventory and ordinary fluctuations in deposits from international customers. The Company does adjust product forecast, order quantities and safety stock based on changes in demand patterns in order to manage inventory levels.

 

As of December 31, 2017, the Company was party to a Loan and Security Agreement, dated February 27, 2017, with Summit Financial Resources, L.P. (the “Credit Agreement”), under which the Company had $2,000,000 available for borrowing (the “Credit Facility”). The Company’s obligations under the Credit Facility are secured by all of the Company’s personal property, both tangible and intangible, pursuant to the terms and subject to the conditions set forth in the Credit Agreement. Availability of funds under the Credit Agreement is based on the Company’s accounts receivable and inventory but will not exceed $2,000,000.00. At December 31, 2017 availability under the Credit Agreement was $2,000,000. At December 31, 2017, the Company expected that it will use the Credit Facility to finance the Company’s operations in the short term.

 

15

 

 

The Credit Facility will be available, subject to its terms, on a revolving basis until it expires on February 27, 2019. Advances will bear interest at a rate equal to 2.00% in excess of the prime rate as reported in the Wall Street Journal and subject to a minimum availability fee of 0.25% (25 basis points) per month on the maximum availability ($5,000 per month). In addition to interest, the Credit facility requires that the Company pay the lender a monthly administration fee in an amount equal to forty-seven hundredths percent (0.47%) of the average outstanding daily principal amount of loan advances for the each calendar month, or portion thereof.

 

Under the Credit Agreement, advances are generally subject to customary borrowing conditions and to Summit’s sole discretion to fund the advances. The Credit Agreement also contains covenants with which the Company must comply during the term of the Credit Facility. Among other things, such covenants require the Company to maintain insurance on the collateral, operate in the ordinary course and not engage in a change of control, dissolve or wind up the Company. In the event of default, interest is calculated on a variable interest rate equal to 20.00% above the prime rate, adjusted as of the date of any change in the prime rate.

 

At December 31, 2017, the Company had no aggregate indebtedness, including capital lease obligations, short-term debt, and long term debt.

 

The Company was in compliance with all of the covenants associated with the Credit Facility at December 31, 2017. 

 

Litigation and Contingencies

 

The Company becomes, from time to time, a party to personal injury litigation arising out of incidents involving the use of its products. The Company believes that any potential judgments resulting from these claims over its self-insured retention will be covered by the Company’s product liability insurance. See Part II, Item 1 – Legal Proceedings, below, for more information concerning litigation.

 

Critical Accounting Policies

 

The impact and any associated risks related to the Company’s critical accounting policies on business operations are discussed throughout “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” where such policies affect the Company’s reported and expected financial results. For a detailed discussion on the application of these and other accounting policies, see the Company’s Annual Report on Form 10-K for the year ended June 30, 2017.

 

16

 

 

Recently Issued Accounting Guidance

 

See Note 1 – Summary of Significant Accounting and Reporting Policies for more information on recent accounting pronouncements and their impact, if any, on the Company’s financial statements. Management believes there have been no material changes to our critical accounting policies.

 

Item 3.Quantitative and Qualitative Disclosure about Market Risk

 

At December 31, 2017, the Company did not have any debt outstanding. The Credit Facility bears interest at a rate using the Prime Rate, as reported in the Wall Street Journal, as the basis, and therefore is subject to additional expense should there be an increase in market interest rates while borrowing on the revolving credit facility.

 

The Company had no holdings of derivative financial or commodity instruments at December 31, 2017. The Company has international sales; however these sales are denominated in U.S. dollars, mitigating foreign exchange rate fluctuation risk.

 

Item 4.Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

The Company maintains controls and procedures designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon their evaluation of those controls and procedures performed as of December 31, 2017, the Chief Executive Officer and Chief Financial Officer of the Company concluded that its disclosure controls and procedures were effective.

 

Changes in internal control over financial reporting

 

There were no changes in the Company’s internal control over financial reporting during the quarter ended December 31, 2017 that have materially affected, or are reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

17

 

 

Part II.OTHER INFORMATION

 

Item 1.Legal Proceedings

 

Stuyvesant Falls Power Litigation. The Company is currently involved in litigation with Niagara Mohawk Power Corporation d/b/a National Grid (“Niagara”), which provides electrical power to the Company’s facility in Stuyvesant Falls, New York, and one other party. The Company maintains in its defense of the lawsuit that it is entitled to a certain amount of free electricity based on covenants running with the land which have been honored for more than a century. After the commencement of the litigation, Niagara began sending invoices to the Company for electricity used at the Company’s Stuyvesant Falls plant. Niagara’s attempts to collect such invoices were stopped in December 2010 by a temporary restraining order. Among other things, Niagara seeks as damages the value of electricity received by the Company without charge. The total value of electricity at issue in the litigation is not known with certainty and Niagara has alleged different amounts of damages. Niagara alleged in its Second Amended Verified Complaint, dated February 6, 2012, damages of approximately $469,000 in free electricity from May 2003 through May 2010. Niagara also alleged in its Motion For Summary Judgment, filed on March 14, 2014, damages of approximately $492,000 in free electricity from May 2010 through the date of the filing. In April 2015, Allied received an invoice for electrical power at the Stuyvesant Falls plant with an “Amount Due” balance of $696,000 as of March 31, 2015 without any description as to the period of time covered by the invoice.

 

The Company filed a Motion for Summary Judgment on March 14, 2014, seeking dismissal of Niagara’s claims and oral arguments on the motions were held on June 13, 2014. On October 1, 2014, the Court granted the Company’s motion, denied Niagara’s motion and ruled that the Company is entitled to receive electrical power pursuant to the power covenants. On October 26 and October 30, 2014, Niagara and the other party filed separate notices of appeal of the Court’s decision. On March 31, 2016 the Supreme Court of New York, Appellate Division, Third Department reversed the trial court decision and held that the free power covenants are no longer enforceable. The Company’s application for leave to appeal this ruling was dismissed as premature by the New York Court of Appeals on September 20, 2016. On May 26, 2017 the Company again moved for leave to appeal the March 31, 2016 decision. That motion was granted on October 7, 2017 by the New York State Court of Appeals.

 

The appellate decision terminated the enforceability of the free power covenants as of March 31, 2016. The appellate decision did not order the Company to pay any amounts for power consumed prior to such date and the Company believes that it is not liable for any such damages as a result of the appellate decision. On December 21, 2016, Niagara filed a motion to the trial court asking that it hold additional proceedings to establish what damages, if any, are owed to Niagara as the result of the appellate decision. The Company filed its response on January 23, 2017. On April 25, 2017, the court denied Niagara’s motion in its entirety finding that no damages could be awarded based on the Appellate Division’s decision. Niagara has filed a Notice of Appeal from that decision, but to date, has not filed the appeal.

 

As of December 31, 2017, the Company has not recorded a provision for this matter. The Company commenced paying for power at the Stuyvesant Falls facility in April 2016.

 

18

 

 

Item 6.Exhibits

 

(a) Exhibits:

 

31.1 Certification of Chief Executive Officer (filed herewith)

 

31.2 Certification of Chief Financial Officer (filed herewith)

 

32.1 Sarbanes-Oxley Certification of Chief Executive Officer (furnished herewith)*

 

32.2 Sarbanes-Oxley Certification of Chief Financial Officer (furnished herewith)*

 

101.INS XBRL Instance Document**

 

101.SCH XBRL Taxonomy Extension Schema Document**

 

101.CAL XBRL Taxonomy Extension Calculation Linkbase Document**

 

101.DEF XBRL Taxonomy Extension Definition Linkbase Document**

 

101.LAB XBRL Taxonomy Extension Label Linkbase Document**

 

101.PRE XBRL Taxonomy Extension Presentation Linkbase Document**

 

*Notwithstanding any incorporation of this Quarterly Report on Form 10-Q in any other filing by the Registrant, Exhibits furnished herewith and designated with an asterisk (*) shall not be deemed incorporated by reference to any other filing under the Securities Act of 1933 or the Securities Exchange Act of 1934 unless specifically otherwise set forth therein.

 

**Filed herewith as Exhibit 101 are the following materials formatted in XBRL: (i) Statement of Operations, (ii) Balance Sheet, (iii) Statement of Cash Flows and (iv) Notes to Financial Statements.

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ALLIED HEALTHCARE PRODUCTS, INC.
   
  /s/ Daniel C. Dunn
  Daniel C. Dunn
  Chief Financial Officer
  Date: February 14, 2018

 

19

 

 EX-31.1 2 tv485561_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1

 

CERTIFICATION

 

I, EARL R. REFSLAND, certify that:

 

1. I have reviewed this Form 10-Q of ALLIED HEALTHCARE PRODUCTS, INC.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: February 14, 2018 /s/ EARL R. REFSLAND
  Earl. R. Refsland
  President & Chief Executive Officer

 

 

 

 EX-31.2 3 tv485561_ex31-2.htm EXHIBIT 31.2

 

Exhibit 31.2

 

CERTIFICATION

 

I, DANIEL C. DUNN, certify that:

 

1. I have reviewed this Form 10-Q of ALLIED HEALTHCARE PRODUCTS, INC.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: February 14, 2018 /s/ DANIEL C. DUNN
  Daniel C. Dunn
 

Vice President, Chief Financial Officer & Secretary

 

 

 

 EX-32.1 4 tv485561_ex32-1.htm EXHIBIT 32.1

 

Exhibit 32.1

 

CERTIFICATION Pursuant to 18 U.S.C. § 1350

 

The undersigned officer of ALLIED HEALTHCARE PRODUCTS, INC. (the "Company"), hereby certifies, to such officer's knowledge, that the Company's Quarterly Report on Form 10-Q for the Company’s fiscal quarter ended December 31, 2017 (the "Report") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

/s/ Earl R. Refsland

  Earl R. Refsland
 

President & Chief Executive Officer

February 14, 2018  

 

 

 

 EX-32.2 5 tv485561_ex32-2.htm EXHIBIT 32.2

 

Exhibit 32.2

 

CERTIFICATION Pursuant to 18 U.S.C. § 1350

 

The undersigned officer of ALLIED HEALTHCARE PRODUCTS, INC. (the "Company"), hereby certifies, to such officer's knowledge, that the Company's Quarterly Report on Form 10-Q for the Company’s fiscal quarter ended December 31, 2017 (the "Report") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

/s/ Daniel C. Dunn

  Daniel C. Dunn
  Vice President, Chief Financial Officer & Secretary
February 14, 2018

 

 

 

 EX-101.INS 6 ahpi-20171231.xml XBRL INSTANCE DOCUMENT 0000874710 2012-01-28 2012-02-06 0000874710 2018-01-31 0000874710 2017-02-01 2017-02-27 0000874710 2014-03-01 2014-03-14 0000874710 2017-06-30 0000874710 2014-07-01 2015-03-31 0000874710 2016-07-01 2016-12-31 0000874710 2017-07-01 2017-12-31 0000874710 2016-10-01 2016-12-31 0000874710 2017-10-01 2017-12-31 0000874710 2017-12-31 0000874710 2016-06-30 0000874710 2016-12-31 0000874710 us-gaap:SeriesAPreferredStockMember 2017-12-31 0000874710 us-gaap:SeriesAPreferredStockMember 2017-06-30 0000874710 us-gaap:RevolvingCreditFacilityMember ahpi:SummitFinancialResourcesLpMember 2017-02-27 0000874710 us-gaap:RevolvingCreditFacilityMember ahpi:SummitFinancialResourcesLpMember 2017-12-31 0000874710 ahpi:SummitFinancialResourcesLpMember us-gaap:RevolvingCreditFacilityMember 2017-02-01 2017-02-27 0000874710 us-gaap:RevolvingCreditFacilityMember ahpi:SummitFinancialResourcesLpMember us-gaap:PrimeRateMember 2017-12-31 0000874710 us-gaap:MaximumMember 2017-12-01 2017-12-22 0000874710 us-gaap:MinimumMember 2017-12-01 2017-12-22 0000874710 us-gaap:MinimumMember 2017-10-01 2017-12-31 0000874710 us-gaap:MinimumMember 2017-07-01 2017-12-31 0000874710 us-gaap:MaximumMember 2017-10-01 2017-12-31 0000874710 us-gaap:MaximumMember 2017-07-01 2017-12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 10-Q false 2017-12-31 2018 Q2 ALLIED HEALTHCARE PRODUCTS INC 0000874710 --06-30 Smaller Reporting Company AHPI 4013537 8268978 8718602 6573722 6809684 1695256 1908918 10 334 -380693 -374700 -244307 -373401 -244132 -374700 -185 -1633 5734041 3573712 3362438 9106188 8511954 19688 12555 243492 315678 12943880 13198329 5278595 800 995704 547377 683763 0 20516 18769852 19636649 2079731 1440403 1650417 2009966 3730148 3450369 0 0 0 0 52139 52139 48486743 48485390 -12518390 -11370461 20980788 20980788 15039704 16186280 18769852 19636649 1202 1353 -816950 212350 -24321 594234 6297 7133 -994904 11497 0 -11497 0 -856470 -994904 1703663 847193 -39633 -72186 -500377 639328 -602974 -359549 -844973 -1191035 -1147929 562963 475962 472699 468839 7902227 7271908 2320593 2368855 1589331 1597648 469000 492000 696000 2000000 2000000 2019-02-27 0.0200 0.0047 0.200 0.0450 16615455 16709391 13349469 13456965 3265986 3252426 2153050 2068657 4277518 4442776 -1011532 -1190350 225 986 -236 -1671 -175 -1299 -11 -685 -1011543 -1191035 -0.09 -0.09 -0.29 -0.30 -0.09 -0.09 -0.29 -0.30 170000 170000 0.01 0.01 1500000 1500000 0 0 0 0 0.01 0.01 200000 200000 0 0 0 0 0.01 0.01 30000000 30000000 5213902 5213902 4013537 4013537 1200365 1200365 1076 10641 136386 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>1. Summary of Significant Accounting and Reporting Policies</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basis of Presentation</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The accompanying unaudited financial statements of Allied Healthcare Products, Inc. (the &#8220;Company&#8221;) have been prepared in accordance with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should be read in conjunction with the financial statements and notes to the financial statements thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2017.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-WEIGHT: normal">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recently Issued Accounting Guidance</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.4in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In May 2014, the FASB and International Accounting Standards Board jointly issued new principles-based accounting guidance for revenue recognition that will supersede virtually all existing revenue guidance. The core principle of this guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. To achieve the core principle, the guidance establishes the following five steps: 1) identify the contract(s) with a customer, 2) identify the performance obligation in the contract, 3) determine the transaction price, 4) allocate the transaction price to the performance obligations in the contract, and 5) recognize revenue when (or as) the entity satisfies a performance obligation. The guidance also details the accounting treatment for costs to obtain or fulfill a contract. Lastly, disclosure requirements have been enhanced to provide sufficient information to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. This guidance&#160;was effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. In July 2015, the FASB affirmed its proposal to defer the effective date by one year. In May 2016, the FASB issued improvements and practical expedients to the standard that included clarification of the collectability criterion, noncash considerations as well as clarification of options at transition. In December 2016, the FASB issued additional corrections and improvements. The Company is in the process of evaluating the impact of this guidance.&#160;This new guidance,&#160;will likely&#160;result in a change in the nature and extent of the related footnote disclosures. The Company plans to adopt the new guidance when effective and presently anticipates adopting on a modified retrospective basis to each prior reporting period presented with the election of applicable practical expedients.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.4in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.4in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases (Topic 842)&#8221; (&#8220;ASU 2016-02&#8221;), which requires lessees to recognize assets and liabilities for leases with lease terms of more than 12 months and disclose key information about leasing arrangements. Consistent with current U.S. GAAP, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. The update is effective for reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is in the process of evaluating the impact of this update on its financial statements.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fair Value of Financial Instruments</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company&#8217;s financial instruments consist of cash and cash equivalents, accounts receivable and accounts payable. The carrying amounts for cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Basis of Presentation</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The accompanying unaudited financial statements of Allied Healthcare Products, Inc. (the &#8220;Company&#8221;) have been prepared in accordance with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should be read in conjunction with the financial statements and notes to the financial statements thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2017.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Recently Issued Accounting Guidance</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.4in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In May 2014, the FASB and International Accounting Standards Board jointly issued new principles-based accounting guidance for revenue recognition that will supersede virtually all existing revenue guidance. The core principle of this guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. To achieve the core principle, the guidance establishes the following five steps: 1) identify the contract(s) with a customer, 2) identify the performance obligation in the contract, 3) determine the transaction price, 4) allocate the transaction price to the performance obligations in the contract, and 5) recognize revenue when (or as) the entity satisfies a performance obligation. The guidance also details the accounting treatment for costs to obtain or fulfill a contract. Lastly, disclosure requirements have been enhanced to provide sufficient information to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. This guidance&#160;was effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. In July 2015, the FASB affirmed its proposal to defer the effective date by one year. In May 2016, the FASB issued improvements and practical expedients to the standard that included clarification of the collectability criterion, noncash considerations as well as clarification of options at transition. In December 2016, the FASB issued additional corrections and improvements. The Company is in the process of evaluating the impact of this guidance.&#160;This new guidance,&#160;will likely&#160;result in a change in the nature and extent of the related footnote disclosures. The Company plans to adopt the new guidance when effective and presently anticipates adopting on a modified retrospective basis to each prior reporting period presented with the election of applicable practical expedients.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.4in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.4in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases (Topic 842)&#8221; (&#8220;ASU 2016-02&#8221;), which requires lessees to recognize assets and liabilities for leases with lease terms of more than 12 months and disclose key information about leasing arrangements. Consistent with current U.S. GAAP, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. The update is effective for reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is in the process of evaluating the impact of this update on its financial statements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Fair Value of Financial Instruments</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company&#8217;s financial instruments consist of cash and cash equivalents, accounts receivable and accounts payable. The carrying amounts for cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>2. Inventories</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Inventories are comprised as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;30,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Work-in progress</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>472,699</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>468,839</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Component parts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,902,227</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,271,908</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,320,593</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,368,855</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Reserve for obsolete and excess inventories</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,589,331)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,597,648)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>9,106,188</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,511,954</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Inventories are comprised as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;30,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Work-in progress</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>472,699</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>468,839</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Component parts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,902,227</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,271,908</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,320,593</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,368,855</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Reserve for obsolete and excess inventories</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,589,331)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,597,648)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>9,106,188</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,511,954</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>3. Earnings per share</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Basic earnings per share are based on the weighted average number of shares of all common stock outstanding during the period. Diluted earnings per share are based on the sum of the weighted average number of shares of common stock and common stock equivalents outstanding during the period. The number of <font style="FONT-SIZE: 10pt">basic</font> and diluted shares outstanding for the three and six months ended December 31, 2017 and 2016 were 4,013,537.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 4013537 4013537 4013537 4013537 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>5. Financing</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On February 27, 2017, Allied Healthcare Products, Inc. (the &#8220;Company&#8221;) entered into a Loan and Security Agreement (the &#8220;Credit Agreement&#8221;) with Summit Financial Resources, L.P. (&#8220;Summit&#8221;) pursuant to which the Company obtained a secured revolving credit facility (the &#8220;Credit Facility&#8221;). The Company&#8217;s obligations under the Credit Facility are secured by all of the Company&#8217;s personal property, both tangible and intangible, pursuant to the terms and subject to the conditions set forth in the Credit Agreement. Availability of funds under the Credit Agreement is based on the Company&#8217;s accounts receivable and inventory but will not exceed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000,000</font>. At December 31, 2017 availability under the agreement was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000,000</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Credit Facility will be available, subject to its terms, on a revolving basis until it expires on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">February 27, 2019</font>, at which time all amounts outstanding under the Credit Facility will be due and payable. Advances will bear interest at a rate equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.00</font>% in excess of the prime rate as reported in the Wall Street Journal. Interest is computed based on the actual number of days elapsed over a year of 360 days. In addition to interest, the Credit facility requires that the Company pay the lender a monthly administration fee in an amount equal to forty-seven hundredths percent (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.47</font>%) of the average outstanding daily principal amount of loan advances for the each calendar month, or portion thereof.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Regardless of the amount borrowed under the Credit Facility, the Company will pay a minimum amount of .25% (25 basis points) per month on the maximum availability ($5,000 per month). In the event the Company prepays or terminates the Credit Facility, the Company will be obligated to pay an amount equal to twelve months of minimum monthly payments, minus the number of months elapsed since the effective date of the Credit Agreement.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Under the Credit Agreement, advances are generally subject to customary borrowing conditions and to Summit&#8217;s sole discretion to fund the advances. The Credit Agreement also contains covenants with which the Company must comply during the term of the Credit Facility. Among other things, such covenants require the Company to maintain insurance on the collateral, operate in the ordinary course and not engage in a change of control, dissolve or wind up the Company.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Credit Agreement also contains certain events of default including, without limitation: the failure to make payments when due; the material breach of representations or warranties contained in the Credit Agreement or other loan documents; cross-default with other indebtedness of the Company; the entry of judgments or fines that may have a material adverse effect on the Company; failure to comply with the observance or performance of covenants contained in the Credit Agreement or other loan documents; insolvency of the Company, appointment of a receiver, commencement of bankruptcy or other insolvency proceedings; dissolution of the Company; the attachment of any state or federal tax lien; attachment or levy upon or seizure of the Company&#8217;s property; or any change in the Company&#8217;s condition that may have a material adverse effect. After an event of default, and upon the continuation thereof, the principal amount of all loans made under the Credit Facility would bear interest at a rate per annum equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20.00</font>% above the otherwise applicable interest rate (provided, that the interest rate may not exceed the highest rate permissible under law), and Summit would have the option to accelerate maturity and payment of the Company&#8217;s obligations under the Credit Facility.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">At December 31, 2017, the Company had no aggregate indebtedness, including capital lease obligations, short-term debt and long term debt. The prime rate as reported in the Wall Street Journal was <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.50</font>% on December 31, 2017.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company was in compliance with all of the covenants associated with the Credit Facility at December 31, 2017.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> the Company will pay a minimum amount of .25% (25 basis points) per month on the maximum availability ($5,000 per month). <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>6. Income Taxes</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company accounts for income taxes under ASC Topic 740: &#8220;Income Taxes.&#8221; Under ASC 740, the deferred tax provision is determined using the liability method, whereby deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and income tax bases of assets and liabilities using presently enacted tax rates. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.4in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In the three and six months ended December 31, 2017 the Company recorded the tax benefit of losses incurred in the amount of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">367,000</font>, respectively.&#160; As the realization of the tax benefit of the net operating loss is not assured an additional valuation allowance of a like amount was recorded.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">For the three and six months ended December 31, 2016 the Company recorded the tax benefit of losses incurred in the amount of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">130,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">436,000</font>. As the realization of the tax benefit of the net operating loss is not assured an additional valuation allowance of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">130,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">436,000</font> was recorded.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.4in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0px" align="left"><b><i>U.S. Tax Reform</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0px" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On December 22, 2017, President Trump signed into law new tax legislation commonly referred to as the Tax Cuts and Jobs Act (the &#8220;TCJA&#8221;), which became effective January 1, 2018. The TCJA significantly revises U.S. tax law by, among other provisions lowering the U.S. federal statutory income tax rate from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35</font>% to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 21</font>%, and eliminating or reducing certain income tax deductions.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">ASC Topic 740, requires the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. However, due to the complexity and significance of the TCJA&#8217;s provisions, the SEC staff issued Staff Accounting Bulletin No. 118 (&#8220;SAB 118&#8221;) on December 22, 2017, which allows companies to record the tax effects of the TCJA on a provisional basis based on a reasonable estimate, and then, if necessary, subsequently adjust such amounts during a limited measurement period as more information becomes available. The measurement period ends when a company has obtained, prepared, and analyzed the information necessary to finalize its accounting, but cannot extend beyond one year from enactment.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the second quarter of fiscal 2018, the Company recorded a one-time charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">136,386</font> within its income tax provision in connection with the TCJA, all of which related to the revaluation of the Company&#8217;s deferred tax assets and liabilities net of a resultant impact of the revaluation on the recorded valuation allowance. This one-time charge, which was recorded on a provisional basis, impacted the Company&#8217;s&#160; effective tax rate by increasing it from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>% to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 56</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 13</font>% for the three-month and six-month periods ended December 31, 2017, respectively, and lowered its basic and diluted earnings per share by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.03</font> during each of these periods. The provisional amounts were based on the Company&#8217;s present interpretations of the TCJA and current available information, including assumptions and expectations about future events, such as its projected financial performance, and are subject to further refinement as additional information becomes available (including the Company&#8217;s actual full fiscal 2018 results of operations and financial condition, as well as potential new or interpretative guidance issued by the FASB or the Internal Revenue Service and other tax agencies) and further analyses are completed.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 75000 367000 130000 436000 130000 436000 4013537 4013537 4013537 4013537 4013537 4013537 4013537 4013537 136386 0 136386 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left"><b>4. Commitments and Contingencies</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Legal Claims</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.4in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company is subject to various investigations, claims and legal proceedings covering a wide range of matters that arise in the ordinary course of its business activities. The Company intends to continue to conduct business in such a manner as to avert any FDA action seeking to interrupt or suspend manufacturing or require any recall or modification of products.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.4in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has recognized the costs and associated liabilities only for those investigations, claims and legal proceedings for which, in its view, it is probable that liabilities have been incurred and the related amounts are estimable. Based upon information currently available, management believes that existing accrued liabilities are sufficient.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Stuyvesant Falls Power Litigation.</u> The Company is currently involved in litigation with Niagara Mohawk Power Corporation d/b/a National Grid (&#8220;Niagara&#8221;), which provides electrical power to the Company&#8217;s facility in Stuyvesant Falls, New York, and one other party. The Company maintains in its defense of the lawsuit that it is entitled to a certain amount of free electricity based on covenants running with the land which have been honored for more than a century. After the commencement of the litigation, Niagara began sending invoices to the Company for electricity used at the Company&#8217;s Stuyvesant Falls plant. Niagara&#8217;s attempts to collect such invoices were stopped in December 2010 by a temporary restraining order. Among other things, Niagara seeks as damages the value of electricity received by the Company without charge. The total value of electricity at issue in the litigation is not known with certainty and Niagara has alleged different amounts of damages. Niagara alleged in its Second Amended Verified Complaint, dated February 6, 2012, damages of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">469,000</font> in free electricity from May 2003 through May 2010. Niagara also alleged in its Motion For Summary Judgment, filed on March 14, 2014, damages of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">492,000</font> in free electricity from May 2010 through the date of the filing. In April 2015, Allied received an invoice for electrical power at the Stuyvesant Falls plant with an &#8220;Amount Due&#8221; balance of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">696,000</font> as of March 31, 2015 without any description as to the period of time covered by the invoice.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company filed a Motion for Summary Judgment on March 14, 2014, seeking dismissal of Niagara&#8217;s claims and oral arguments on the motions were held on June 13, 2014. On October 1, 2014, the Court granted the Company&#8217;s motion, denied Niagara&#8217;s motion and ruled that the Company is entitled to receive electrical power pursuant to the power covenants. On October 26 and October 30, 2014, Niagara and the other party filed separate notices of appeal of the Court&#8217;s decision. On March 31, 2016 the Supreme Court of New York, Appellate Division, Third Department reversed the trial court decision and held that the free power covenants are no longer enforceable. The Company&#8217;s application for leave to appeal this ruling was dismissed as premature by the New York Court of Appeals on September 20, 2016. On May 26, 2017 the Company again moved for leave to appeal the March 31, 2016 decision. That motion was granted on October 7, 2017 by the New York State Court of Appeals.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.4in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The appellate decision terminated the enforceability of the free power covenants as of March 31, 2016. The appellate decision did not order the Company to pay any amounts for power consumed prior to such date and the Company believes that it is not liable for any such damages as a result of the appellate decision. On December 21, 2016, Niagara filed a motion to the trial court asking that it hold additional proceedings to establish what damages, if any, are owed to Niagara as the result of the appellate decision. The Company filed its response on January 23, 2017. On April 25, 2017, the court denied Niagara&#8217;s motion in its entirety finding that no damages could be awarded based on the Appellate Division&#8217;s decision. Niagara has filed a Notice of Appeal from that decision, but to date, has not filed the appeal.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of December 31, 2017, the Company has not recorded a provision for this matter. The Company commenced paying for power at the Stuyvesant Falls facility in April 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Employment Contract</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has entered into an employment contract with its chief executive officer with annual renewals. The contract includes termination without cause and change of control provisions, under which the chief executive officer is entitled to receive specified severance payments generally equal to two times ending annual salary if the Company terminates his employment without cause or he voluntarily terminates his employment with &#8220;good reason.&#8221; &#8220;Good Reason&#8221; generally includes changes in the scope of his duties or location of employment but also includes (i) the Company&#8217;s written election not to renew the Employment Agreement and (ii) certain voluntary resignations by the chief executive officer following a &#8220;Change of Control&#8221; as defined in the Agreement.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0.03 0.35 0.21 0 0 0.56 0.13 EX-101.SCH 7 ahpi-20171231.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - STATEMENT OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - BALANCE SHEET link:presentationLink link:definitionLink link:calculationLink 104 - Statement - BALANCE SHEET [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 105 - Statement - STATEMENT OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 106 - Disclosure - Summary of Significant Accounting and Reporting Policies link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Earnings per share link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Financing link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Summary of Significant Accounting and Reporting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Inventories (Details) link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Earnings per share (Details Textual) link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Financing (Details Textual) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 ahpi-20171231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 ahpi-20171231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 ahpi-20171231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 ahpi-20171231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document And Entity Information - shares
 6 Months Ended
Dec. 31, 2017
Jan. 31, 2018
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Dec. 31, 2017  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q2  
Entity Registrant Name ALLIED HEALTHCARE PRODUCTS INC  
Entity Central Index Key 0000874710  
Current Fiscal Year End Date --06-30  
Entity Filer Category Smaller Reporting Company  
Trading Symbol AHPI  
Entity Common Stock, Shares Outstanding   4,013,537
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
STATEMENT OF OPERATIONS - USD ($)
 3 Months Ended 6 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Net sales $ 8,718,602 $ 8,268,978 $ 16,615,455 $ 16,709,391
Cost of sales 6,809,684 6,573,722 13,349,469 13,456,965
Gross profit 1,908,918 1,695,256 3,265,986 3,252,426
Selling, general and administrative expenses 2,153,050 2,068,657 4,277,518 4,442,776
Loss from operations (244,132) (373,401) (1,011,532) (1,190,350)
Other (income) expenses:        
Interest income (10) (334) (225) (986)
Other, net 185 1,633 236 1,671
Nonoperating Income (Expense) 175 1,299 11 685
Loss before income taxes (244,307) (374,700) (1,011,543) (1,191,035)
Provision for income taxes 136,386 0 136,386 0
Net loss $ (380,693) $ (374,700) $ (1,147,929) $ (1,191,035)
Basic loss per share $ (0.09) $ (0.09) $ (0.29) $ (0.30)
Diluted loss per share $ (0.09) $ (0.09) $ (0.29) $ (0.30)
Weighted average shares outstanding - basic 4,013,537 4,013,537 4,013,537 4,013,537
Weighted average shares outstanding - diluted 4,013,537 4,013,537 4,013,537 4,013,537
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
BALANCE SHEET - USD ($)
Dec. 31, 2017
Jun. 30, 2017
Current assets:    
Cash and cash equivalents $ 800 $ 995,704
Accounts receivable, net of allowances of $170,000 3,573,712 3,362,438
Inventories, net 9,106,188 8,511,954
Income tax receivable 19,688 12,555
Other current assets 243,492 315,678
Total current assets 12,943,880 13,198,329
Property, plant and equipment, net 5,278,595 5,734,041
Deferred income taxes 547,377 683,763
Other assets, net 0 20,516
Total assets 18,769,852 19,636,649
Current liabilities:    
Accounts payable 2,079,731 1,440,403
Other accrued liabilities 1,650,417 2,009,966
Total current liabilities 3,730,148 3,450,369
Commitments and contingencies
Stockholders’ equity:    
Preferred stock 0 0
Common stock; $0.01 par value; 30,000,000 shares authorized; 5,213,902 shares issued at December 31, 2017 and June 30, 2017; 4,013,537 shares outstanding at December 31, 2017 and June 30, 2017 52,139 52,139
Additional paid-in capital 48,486,743 48,485,390
Accumulated deficit (12,518,390) (11,370,461)
Less treasury stock, at cost; 1,200,365 shares at December 31, 2017 and June 30, 2017, respectively (20,980,788) (20,980,788)
Total stockholders’ equity 15,039,704 16,186,280
Total liabilities and stockholders’ equity 18,769,852 19,636,649
Series A Preferred Stock [Member]    
Stockholders’ equity:    
Preferred stock $ 0 $ 0
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
BALANCE SHEET [Parenthetical] - USD ($)
Dec. 31, 2017
Jun. 30, 2017
Allowances for accounts receivable (in dollars) $ 170,000 $ 170,000
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized 1,500,000 1,500,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized 30,000,000 30,000,000
Common stock, shares issued 5,213,902 5,213,902
Common stock, shares outstanding 4,013,537 4,013,537
Treasury stock, at cost 1,200,365 1,200,365
Series A Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized 200,000 200,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
STATEMENT OF CASH FLOWS - USD ($)
 6 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Cash flows from operating activities:    
Net loss $ (1,147,929) $ (1,191,035)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 475,962 562,963
Stock based compensation 1,353 1,202
Provision for doubtful accounts and sales returns and allowances 1,076 10,641
Deferred taxes 136,386 0
Changes in operating assets and liabilities:    
Accounts receivable (212,350) 816,950
Inventories (594,234) 24,321
Income tax receivable (7,133) (6,297)
Other current assets 72,186 39,633
Accounts payable 639,328 (500,377)
Other accrued liabilities (359,549) (602,974)
Net cash used in operating activities (994,904) (844,973)
Cash flows from investing activities:    
Capital expenditures 0 (11,497)
Net cash used in investing activities 0 (11,497)
Net decrease in cash and cash equivalents (994,904) (856,470)
Cash and cash equivalents at beginning of period 995,704 1,703,663
Cash and cash equivalents at end of period $ 800 $ 847,193
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting and Reporting Policies
 6 Months Ended
Dec. 31, 2017
Accounting Policies [Abstract]  
Significant Accounting Policies [Text Block]
1. Summary of Significant Accounting and Reporting Policies
 
Basis of Presentation
 
The accompanying unaudited financial statements of Allied Healthcare Products, Inc. (the “Company”) have been prepared in accordance with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should be read in conjunction with the financial statements and notes to the financial statements thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2017.
 
Recently Issued Accounting Guidance
 
In May 2014, the FASB and International Accounting Standards Board jointly issued new principles-based accounting guidance for revenue recognition that will supersede virtually all existing revenue guidance. The core principle of this guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. To achieve the core principle, the guidance establishes the following five steps: 1) identify the contract(s) with a customer, 2) identify the performance obligation in the contract, 3) determine the transaction price, 4) allocate the transaction price to the performance obligations in the contract, and 5) recognize revenue when (or as) the entity satisfies a performance obligation. The guidance also details the accounting treatment for costs to obtain or fulfill a contract. Lastly, disclosure requirements have been enhanced to provide sufficient information to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. This guidance was effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. In July 2015, the FASB affirmed its proposal to defer the effective date by one year. In May 2016, the FASB issued improvements and practical expedients to the standard that included clarification of the collectability criterion, noncash considerations as well as clarification of options at transition. In December 2016, the FASB issued additional corrections and improvements. The Company is in the process of evaluating the impact of this guidance. This new guidance, will likely result in a change in the nature and extent of the related footnote disclosures. The Company plans to adopt the new guidance when effective and presently anticipates adopting on a modified retrospective basis to each prior reporting period presented with the election of applicable practical expedients.
  
In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”), which requires lessees to recognize assets and liabilities for leases with lease terms of more than 12 months and disclose key information about leasing arrangements. Consistent with current U.S. GAAP, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. The update is effective for reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is in the process of evaluating the impact of this update on its financial statements.
 
Fair Value of Financial Instruments
 
The Company’s financial instruments consist of cash and cash equivalents, accounts receivable and accounts payable. The carrying amounts for cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments.
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventories
 6 Months Ended
Dec. 31, 2017
Inventory, Net [Abstract]  
Inventory Disclosure [Text Block]
2. Inventories
 
Inventories are comprised as follows:
 
 
 
December 31, 2017
 
June 30, 2017
 
 
 
 
 
 
 
 
 
Work-in progress
 
$
472,699
 
$
468,839
 
Component parts
 
 
7,902,227
 
 
7,271,908
 
Finished goods
 
 
2,320,593
 
 
2,368,855
 
Reserve for obsolete and excess inventories
 
 
(1,589,331)
 
 
(1,597,648)
 
 
 
$
9,106,188
 
$
8,511,954
 
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Earnings per share
 6 Months Ended
Dec. 31, 2017
Earnings Per Share [Abstract]  
Earnings Per Share [Text Block]
3. Earnings per share
 
Basic earnings per share are based on the weighted average number of shares of all common stock outstanding during the period. Diluted earnings per share are based on the sum of the weighted average number of shares of common stock and common stock equivalents outstanding during the period. The number of basic and diluted shares outstanding for the three and six months ended December 31, 2017 and 2016 were 4,013,537.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies
 6 Months Ended
Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block]
4. Commitments and Contingencies
 
Legal Claims
 
The Company is subject to various investigations, claims and legal proceedings covering a wide range of matters that arise in the ordinary course of its business activities. The Company intends to continue to conduct business in such a manner as to avert any FDA action seeking to interrupt or suspend manufacturing or require any recall or modification of products.
  
The Company has recognized the costs and associated liabilities only for those investigations, claims and legal proceedings for which, in its view, it is probable that liabilities have been incurred and the related amounts are estimable. Based upon information currently available, management believes that existing accrued liabilities are sufficient.
 
Stuyvesant Falls Power Litigation. The Company is currently involved in litigation with Niagara Mohawk Power Corporation d/b/a National Grid (“Niagara”), which provides electrical power to the Company’s facility in Stuyvesant Falls, New York, and one other party. The Company maintains in its defense of the lawsuit that it is entitled to a certain amount of free electricity based on covenants running with the land which have been honored for more than a century. After the commencement of the litigation, Niagara began sending invoices to the Company for electricity used at the Company’s Stuyvesant Falls plant. Niagara’s attempts to collect such invoices were stopped in December 2010 by a temporary restraining order. Among other things, Niagara seeks as damages the value of electricity received by the Company without charge. The total value of electricity at issue in the litigation is not known with certainty and Niagara has alleged different amounts of damages. Niagara alleged in its Second Amended Verified Complaint, dated February 6, 2012, damages of approximately $469,000 in free electricity from May 2003 through May 2010. Niagara also alleged in its Motion For Summary Judgment, filed on March 14, 2014, damages of approximately $492,000 in free electricity from May 2010 through the date of the filing. In April 2015, Allied received an invoice for electrical power at the Stuyvesant Falls plant with an “Amount Due” balance of $696,000 as of March 31, 2015 without any description as to the period of time covered by the invoice.
  
The Company filed a Motion for Summary Judgment on March 14, 2014, seeking dismissal of Niagara’s claims and oral arguments on the motions were held on June 13, 2014. On October 1, 2014, the Court granted the Company’s motion, denied Niagara’s motion and ruled that the Company is entitled to receive electrical power pursuant to the power covenants. On October 26 and October 30, 2014, Niagara and the other party filed separate notices of appeal of the Court’s decision. On March 31, 2016 the Supreme Court of New York, Appellate Division, Third Department reversed the trial court decision and held that the free power covenants are no longer enforceable. The Company’s application for leave to appeal this ruling was dismissed as premature by the New York Court of Appeals on September 20, 2016. On May 26, 2017 the Company again moved for leave to appeal the March 31, 2016 decision. That motion was granted on October 7, 2017 by the New York State Court of Appeals.
  
The appellate decision terminated the enforceability of the free power covenants as of March 31, 2016. The appellate decision did not order the Company to pay any amounts for power consumed prior to such date and the Company believes that it is not liable for any such damages as a result of the appellate decision. On December 21, 2016, Niagara filed a motion to the trial court asking that it hold additional proceedings to establish what damages, if any, are owed to Niagara as the result of the appellate decision. The Company filed its response on January 23, 2017. On April 25, 2017, the court denied Niagara’s motion in its entirety finding that no damages could be awarded based on the Appellate Division’s decision. Niagara has filed a Notice of Appeal from that decision, but to date, has not filed the appeal.
 
As of December 31, 2017, the Company has not recorded a provision for this matter. The Company commenced paying for power at the Stuyvesant Falls facility in April 2016.
 
Employment Contract
 
The Company has entered into an employment contract with its chief executive officer with annual renewals. The contract includes termination without cause and change of control provisions, under which the chief executive officer is entitled to receive specified severance payments generally equal to two times ending annual salary if the Company terminates his employment without cause or he voluntarily terminates his employment with “good reason.” “Good Reason” generally includes changes in the scope of his duties or location of employment but also includes (i) the Company’s written election not to renew the Employment Agreement and (ii) certain voluntary resignations by the chief executive officer following a “Change of Control” as defined in the Agreement.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Financing
 6 Months Ended
Dec. 31, 2017
Debt Disclosure [Abstract]  
Debt Disclosure [Text Block]
5. Financing
 
On February 27, 2017, Allied Healthcare Products, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Credit Agreement”) with Summit Financial Resources, L.P. (“Summit”) pursuant to which the Company obtained a secured revolving credit facility (the “Credit Facility”). The Company’s obligations under the Credit Facility are secured by all of the Company’s personal property, both tangible and intangible, pursuant to the terms and subject to the conditions set forth in the Credit Agreement. Availability of funds under the Credit Agreement is based on the Company’s accounts receivable and inventory but will not exceed $2,000,000. At December 31, 2017 availability under the agreement was $2,000,000.
 
The Credit Facility will be available, subject to its terms, on a revolving basis until it expires on February 27, 2019, at which time all amounts outstanding under the Credit Facility will be due and payable. Advances will bear interest at a rate equal to 2.00% in excess of the prime rate as reported in the Wall Street Journal. Interest is computed based on the actual number of days elapsed over a year of 360 days. In addition to interest, the Credit facility requires that the Company pay the lender a monthly administration fee in an amount equal to forty-seven hundredths percent (0.47%) of the average outstanding daily principal amount of loan advances for the each calendar month, or portion thereof.
 
Regardless of the amount borrowed under the Credit Facility, the Company will pay a minimum amount of .25% (25 basis points) per month on the maximum availability ($5,000 per month). In the event the Company prepays or terminates the Credit Facility, the Company will be obligated to pay an amount equal to twelve months of minimum monthly payments, minus the number of months elapsed since the effective date of the Credit Agreement.
 
Under the Credit Agreement, advances are generally subject to customary borrowing conditions and to Summit’s sole discretion to fund the advances. The Credit Agreement also contains covenants with which the Company must comply during the term of the Credit Facility. Among other things, such covenants require the Company to maintain insurance on the collateral, operate in the ordinary course and not engage in a change of control, dissolve or wind up the Company.
 
The Credit Agreement also contains certain events of default including, without limitation: the failure to make payments when due; the material breach of representations or warranties contained in the Credit Agreement or other loan documents; cross-default with other indebtedness of the Company; the entry of judgments or fines that may have a material adverse effect on the Company; failure to comply with the observance or performance of covenants contained in the Credit Agreement or other loan documents; insolvency of the Company, appointment of a receiver, commencement of bankruptcy or other insolvency proceedings; dissolution of the Company; the attachment of any state or federal tax lien; attachment or levy upon or seizure of the Company’s property; or any change in the Company’s condition that may have a material adverse effect. After an event of default, and upon the continuation thereof, the principal amount of all loans made under the Credit Facility would bear interest at a rate per annum equal to 20.00% above the otherwise applicable interest rate (provided, that the interest rate may not exceed the highest rate permissible under law), and Summit would have the option to accelerate maturity and payment of the Company’s obligations under the Credit Facility.
 
At December 31, 2017, the Company had no aggregate indebtedness, including capital lease obligations, short-term debt and long term debt. The prime rate as reported in the Wall Street Journal was 4.50% on December 31, 2017.
 
The Company was in compliance with all of the covenants associated with the Credit Facility at December 31, 2017.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes
 6 Months Ended
Dec. 31, 2017
Income Tax Disclosure [Abstract]  
Income Tax Disclosure [Text Block]
6. Income Taxes
 
The Company accounts for income taxes under ASC Topic 740: “Income Taxes.” Under ASC 740, the deferred tax provision is determined using the liability method, whereby deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and income tax bases of assets and liabilities using presently enacted tax rates. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. 
 
In the three and six months ended December 31, 2017 the Company recorded the tax benefit of losses incurred in the amount of approximately $75,000 and $367,000, respectively.  As the realization of the tax benefit of the net operating loss is not assured an additional valuation allowance of a like amount was recorded.
 
For the three and six months ended December 31, 2016 the Company recorded the tax benefit of losses incurred in the amount of approximately $130,000 and $436,000. As the realization of the tax benefit of the net operating loss is not assured an additional valuation allowance of approximately $130,000 and $436,000 was recorded.
 
U.S. Tax Reform
 
On December 22, 2017, President Trump signed into law new tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “TCJA”), which became effective January 1, 2018. The TCJA significantly revises U.S. tax law by, among other provisions lowering the U.S. federal statutory income tax rate from 35% to 21%, and eliminating or reducing certain income tax deductions.
 
ASC Topic 740, requires the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. However, due to the complexity and significance of the TCJA’s provisions, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”) on December 22, 2017, which allows companies to record the tax effects of the TCJA on a provisional basis based on a reasonable estimate, and then, if necessary, subsequently adjust such amounts during a limited measurement period as more information becomes available. The measurement period ends when a company has obtained, prepared, and analyzed the information necessary to finalize its accounting, but cannot extend beyond one year from enactment.
 
During the second quarter of fiscal 2018, the Company recorded a one-time charge of $136,386 within its income tax provision in connection with the TCJA, all of which related to the revaluation of the Company’s deferred tax assets and liabilities net of a resultant impact of the revaluation on the recorded valuation allowance. This one-time charge, which was recorded on a provisional basis, impacted the Company’s  effective tax rate by increasing it from 0% and 0% to 56% and 13% for the three-month and six-month periods ended December 31, 2017, respectively, and lowered its basic and diluted earnings per share by $0.03 during each of these periods. The provisional amounts were based on the Company’s present interpretations of the TCJA and current available information, including assumptions and expectations about future events, such as its projected financial performance, and are subject to further refinement as additional information becomes available (including the Company’s actual full fiscal 2018 results of operations and financial condition, as well as potential new or interpretative guidance issued by the FASB or the Internal Revenue Service and other tax agencies) and further analyses are completed.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting and Reporting Policies (Policies)
 6 Months Ended
Dec. 31, 2017
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block]
Basis of Presentation
 
The accompanying unaudited financial statements of Allied Healthcare Products, Inc. (the “Company”) have been prepared in accordance with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should be read in conjunction with the financial statements and notes to the financial statements thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2017.
New Accounting Pronouncements, Policy [Policy Text Block]
Recently Issued Accounting Guidance
 
In May 2014, the FASB and International Accounting Standards Board jointly issued new principles-based accounting guidance for revenue recognition that will supersede virtually all existing revenue guidance. The core principle of this guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. To achieve the core principle, the guidance establishes the following five steps: 1) identify the contract(s) with a customer, 2) identify the performance obligation in the contract, 3) determine the transaction price, 4) allocate the transaction price to the performance obligations in the contract, and 5) recognize revenue when (or as) the entity satisfies a performance obligation. The guidance also details the accounting treatment for costs to obtain or fulfill a contract. Lastly, disclosure requirements have been enhanced to provide sufficient information to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. This guidance was effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. In July 2015, the FASB affirmed its proposal to defer the effective date by one year. In May 2016, the FASB issued improvements and practical expedients to the standard that included clarification of the collectability criterion, noncash considerations as well as clarification of options at transition. In December 2016, the FASB issued additional corrections and improvements. The Company is in the process of evaluating the impact of this guidance. This new guidance, will likely result in a change in the nature and extent of the related footnote disclosures. The Company plans to adopt the new guidance when effective and presently anticipates adopting on a modified retrospective basis to each prior reporting period presented with the election of applicable practical expedients.
  
In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”), which requires lessees to recognize assets and liabilities for leases with lease terms of more than 12 months and disclose key information about leasing arrangements. Consistent with current U.S. GAAP, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. The update is effective for reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is in the process of evaluating the impact of this update on its financial statements.
Fair Value of Financial Instruments, Policy [Policy Text Block]
Fair Value of Financial Instruments
 
The Company’s financial instruments consist of cash and cash equivalents, accounts receivable and accounts payable. The carrying amounts for cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventories (Tables)
 6 Months Ended
Dec. 31, 2017
Inventory, Net [Abstract]  
Schedule of Inventory, Current [Table Text Block]
Inventories are comprised as follows:
 
 
 
December 31, 2017
 
June 30, 2017
 
 
 
 
 
 
 
 
 
Work-in progress
 
$
472,699
 
$
468,839
 
Component parts
 
 
7,902,227
 
 
7,271,908
 
Finished goods
 
 
2,320,593
 
 
2,368,855
 
Reserve for obsolete and excess inventories
 
 
(1,589,331)
 
 
(1,597,648)
 
 
 
$
9,106,188
 
$
8,511,954
 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventories (Details) - USD ($)
Dec. 31, 2017
Jun. 30, 2017
Inventory [Line Items]    
Work-in progress $ 472,699 $ 468,839
Component parts 7,902,227 7,271,908
Finished goods 2,320,593 2,368,855
Reserve for obsolete and excess inventories (1,589,331) (1,597,648)
Inventory, Net $ 9,106,188 $ 8,511,954
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Earnings per share (Details Textual) - shares
 3 Months Ended 6 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Earnings Per Share [Line Items]        
Weighted Average Number of Shares Outstanding, Basic and Diluted 4,013,537 4,013,537 4,013,537 4,013,537
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Details Textual) - USD ($)
 9 Months Ended
Mar. 14, 2014
Feb. 06, 2012
Mar. 31, 2015
Commitments and Contingencies [Line Items]      
Loss Contingency, Damages Sought, Value $ 492,000 $ 469,000 $ 696,000
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Financing (Details Textual) - USD ($)
 1 Months Ended 6 Months Ended
Feb. 27, 2017
Dec. 31, 2017
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage   20.00%
Line of Credit Facility, Expiration Date Feb. 27, 2019  
Line of Credit Facility, Frequency of Payment and Payment Terms   the Company will pay a minimum amount of .25% (25 basis points) per month on the maximum availability ($5,000 per month).
Summit Financial Resources Lp [Member] | Revolving Credit Facility [Member]    
Debt Instrument [Line Items]    
Line Of Credit Facility, Maximum Borrowing Capacity $ 2,000,000  
Debt Instrument, Basis Spread on Variable Rate 2.00%  
Line of Credit Facility, Remaining Borrowing Capacity   $ 2,000,000
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage 0.47%  
Summit Financial Resources Lp [Member] | Revolving Credit Facility [Member] | Prime Rate [Member]    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Effective Percentage   4.50%
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Dec. 22, 2017
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Schedule Of Income Tax Disclosure [Line Items]          
Deferred Other Tax Expense (Benefit)   $ 75,000 $ 130,000 $ 367,000 $ 436,000
Deferred Tax Assets Valuation Allowance Addition Amount   130,000   $ 436,000  
Earnings Per Share, Basic and Diluted       $ 0.03  
Provision for income taxes   $ 136,386 $ 0 $ 136,386 $ 0
Minimum [Member]          
Schedule Of Income Tax Disclosure [Line Items]          
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 21.00%        
Effective Income Tax Rate Reconciliation, Percent   0.00%   0.00%  
Maximum [Member]          
Schedule Of Income Tax Disclosure [Line Items]          
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 35.00%        
Effective Income Tax Rate Reconciliation, Percent   56.00%   13.00%  
EXCEL 30 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 31 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 32 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 34 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 25 100 1 false 6 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.alliedhpi.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - STATEMENT OF OPERATIONS Sheet http://www.alliedhpi.com/role/StatementOfOperations STATEMENT OF OPERATIONS Statements 2 false false R3.htm 103 - Statement - BALANCE SHEET Sheet http://www.alliedhpi.com/role/BalanceSheet BALANCE SHEET Statements 3 false false R4.htm 104 - Statement - BALANCE SHEET [Parenthetical] Sheet http://www.alliedhpi.com/role/BalanceSheetParenthetical BALANCE SHEET [Parenthetical] Statements 4 false false R5.htm 105 - Statement - STATEMENT OF CASH FLOWS Sheet http://www.alliedhpi.com/role/StatementOfCashFlows STATEMENT OF CASH FLOWS Statements 5 false false R6.htm 106 - Disclosure - Summary of Significant Accounting and Reporting Policies Sheet http://www.alliedhpi.com/role/SummaryOfSignificantAccountingAndReportingPolicies Summary of Significant Accounting and Reporting Policies Notes 6 false false R7.htm 107 - Disclosure - Inventories Sheet http://www.alliedhpi.com/role/Inventories Inventories Notes 7 false false R8.htm 108 - Disclosure - Earnings per share Sheet http://www.alliedhpi.com/role/EarningsPerShare Earnings per share Notes 8 false false R9.htm 109 - Disclosure - Commitments and Contingencies Sheet http://www.alliedhpi.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 9 false false R10.htm 110 - Disclosure - Financing Sheet http://www.alliedhpi.com/role/Financing Financing Notes 10 false false R11.htm 111 - Disclosure - Income Taxes Sheet http://www.alliedhpi.com/role/IncomeTaxes Income Taxes Notes 11 false false R12.htm 112 - Disclosure - Summary of Significant Accounting and Reporting Policies (Policies) Sheet http://www.alliedhpi.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies Summary of Significant Accounting and Reporting Policies (Policies) Policies http://www.alliedhpi.com/role/SummaryOfSignificantAccountingAndReportingPolicies 12 false false R13.htm 113 - Disclosure - Inventories (Tables) Sheet http://www.alliedhpi.com/role/InventoriesTables Inventories (Tables) Tables http://www.alliedhpi.com/role/Inventories 13 false false R14.htm 114 - Disclosure - Inventories (Details) Sheet http://www.alliedhpi.com/role/InventoriesDetails Inventories (Details) Details http://www.alliedhpi.com/role/InventoriesTables 14 false false R15.htm 115 - Disclosure - Earnings per share (Details Textual) Sheet http://www.alliedhpi.com/role/EarningsPerShareDetailsTextual Earnings per share (Details Textual) Details http://www.alliedhpi.com/role/EarningsPerShare 15 false false R16.htm 116 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://www.alliedhpi.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) Details http://www.alliedhpi.com/role/CommitmentsAndContingencies 16 false false R17.htm 117 - Disclosure - Financing (Details Textual) Sheet http://www.alliedhpi.com/role/FinancingDetailsTextual Financing (Details Textual) Details http://www.alliedhpi.com/role/Financing 17 false false R18.htm 118 - Disclosure - Income Taxes (Details Textual) Sheet http://www.alliedhpi.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) Details http://www.alliedhpi.com/role/IncomeTaxes 18 false false All Reports Book All Reports ahpi-20171231.xml ahpi-20171231.xsd ahpi-20171231_cal.xml ahpi-20171231_def.xml ahpi-20171231_lab.xml ahpi-20171231_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 36 0001144204-18-009053-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-18-009053-xbrl.zip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end